薈萃國際控股(08041.HK)與一家區塊鏈技術開發公司訂立合作備忘錄
格隆匯12月11日丨薈萃國際控股(08041.HK)發佈公告,於2019年12月11日,薈萃香港與目標公司就建議合作訂立諒解備忘錄。目標公司主要於中國從事區塊鏈技術開發及分佈式雲存儲設備的生產及銷售。
根據諒解備忘錄,薈萃香港與目標公司旨在於區塊鏈技術及分佈式雲存儲領域建立戰略合作關係。
公司稱,公司一直在物色投資機遇,以為其股東提供更佳回報。中國領導人近期談及加快中國區塊鏈技術及產業的創新發展。預計中國區塊鏈及雲相關業務方面將存在巨大機遇。建議合作將令該公司利用目標公司的專業知識及經驗踏足該快速增長及前景光明的領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.